Cargando…
Feasibility of Romiplostim Discontinuation in Adult Thrombopoietin-Receptor Agonist Responsive Patients with Primary Immune Thrombocytopenia: An Observational Retrospective Report in Real Life Clinical Practice
Thrombopoietin mimetics are new treatment options for patients with immune throm-bocytopenia (ITP). Because of their mechanism of action, long-term administration was envisioned in order to maintain effective thrombopoiesis. We report on 30 romiplostim treated patients: 13/27 responders (48%) achiev...
Autores principales: | Carpenedo, Monica, Cantoni, Silvia, Coccini, Veronica, Fedele, Marilena, Morra, Enrica, Pogliani, Enrico Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378205/ https://www.ncbi.nlm.nih.gov/pubmed/25852848 http://dx.doi.org/10.4081/hr.2015.5673 |
Ejemplares similares
-
Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
por: Pecci, Alessandro, et al.
Publicado: (2017) -
Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
por: González-Porras, José R., et al.
Publicado: (2019) -
Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multi-Refractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists
por: Carpenedo, Monica, et al.
Publicado: (2023) -
Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy
por: Napolitano, Mariasanta, et al.
Publicado: (2023) -
Long-Term Use of the Thrombopoietin-Mimetic Romiplostim in Children With Severe Chronic Immune Thrombocytopenia (ITP)
por: Bussel, James B, et al.
Publicado: (2015)